ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.17
0.17%
US Tech 100
18,491.60
-0.06%
S&P 500
5,443.13
0.16%
US Dollar vs CAD
1.37176
0.05%
Bitcoin
59,258.85
-2.24%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Denali Therapeutics Inc (DNLI)

  7. Denali Therapeutics Inc (DNLI) News

DNLI

Denali Therapeutics (DNLI)

Denali Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:DNLI
DateTimeSourceHeadlineSymbolCompany
08/14/20241:00PMGlobeNewswire Inc.Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following IntraveNASDAQ:DNLIDenali Therapeutics Inc
08/13/20247:37PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
08/13/20247:36PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
08/01/20245:52AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DNLIDenali Therapeutics Inc
08/01/20245:48AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
08/01/20245:45AMGlobeNewswire Inc.Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
06/10/20247:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
06/06/20243:26PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
06/04/20245:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
06/04/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
06/04/20245:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
06/03/20247:00AMGlobeNewswire Inc.Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease TherapiesNASDAQ:DNLIDenali Therapeutics Inc
05/31/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
05/07/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
05/07/20243:01PMGlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
05/01/20247:00AMGlobeNewswire Inc.Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialNASDAQ:DNLIDenali Therapeutics Inc
03/01/20243:51PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DNLIDenali Therapeutics Inc
02/27/20247:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
02/27/20247:05AMGlobeNewswire Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
02/27/20247:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
02/27/20247:00AMGlobeNewswire Inc.Denali Therapeutics Announces $500 million Private Placement Equity FinancingNASDAQ:DNLIDenali Therapeutics Inc
02/16/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
02/15/20248:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
02/15/20248:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
02/15/20248:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
02/14/20243:59PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
02/14/20243:43PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
02/13/20247:19PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
02/13/20247:18PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
02/13/20247:17PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DNLI

Your Recent History

USOTC
ASTA
Astra Veda (PK)
USOTC
RXMD
Progressive Care (QB)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
GRST
Ethema Health (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
AXXA
Exxe (PK)
USOTC
SFRX
Seafarer Exploration (PK)
USOTC
GNCP
GNCC Capital (CE)
USOTC
VDRM
ViaDerma (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
AABB
Asia Broadband (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
KGKG
Kona Gold Beverage (PK)
USOTC
GGSM
Gold and GemStone Mining (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved